|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Jean-Paul Clozel||CEO & Director||N/D||N/D||1955|
|Mr. André C. Muller||Exec. VP & CFO||N/D||N/D||1963|
|Dr. Martine Clozel||Exec. VP & Chief Scientific Officer||N/D||N/D||1955|
|Mr. Andrew C. Weiss||Sr. VP and Head of Investor Relations & Corp. Communications||N/D||N/D||1968|
|Dr. Guy Braunstein||Exec. VP & Head of Global Clinical Devel.||N/D||N/D||1956|
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator for the treatment of duchenne muscular dystrophy; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase 1 clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
L'ISS Governance QualityScore di Idorsia Ltd al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.